Mead Johnson announces ad campaign to restore trust in Enfamil
GLENVIEW, Ill. — Mead Johnson Nutrition CEO Stephen Golsby on Thursday announced that the company will be deploying a significant ad campaign to recapture any lost trust among moms because of an Enfamil "pull-and-hold" in December.
Retailers had pulled the product off their shelves out of an abundance of caution — the product had been consumed in the days prior to a child’s death — but both the Food and Drug Administration and the Centers for Disease Control and Prevention later vetted Enfamil from having any link to that tragedy.
"While it is very difficult to quantify the impact at this early date, we believe that misleading headlines and the resultant uncertainty caused some moms to switch from the Enfamil brand and others to start on an alternative formula," Golsby said during a fourth-quarter conference call with analysts. "We responded quickly with appropriate activities, including an extensive e-mail communication, reassuring millions of mothers about the 2,300 quality and safety checks we perform to ensure the integrity of every product that we ship to market."
Golsby asserted that the campaign was necessary despite the fact that many of the moms impacted by the recall will be out of the market by third quarter 2012. "It makes sense because as a consequence of misinformation, misleading headlines and, in our opinion, some inappropriate actions, a large number of parents were highly concerned by what they were hearing, reading and seeing," he said. "Market research data would show us that the trust in Enfamil has been diminished in the eyes of some consumers, and we need to restore that quickly. We’ve been in this business for 106 years, [and] we intend to be in it for another 100 years. We are going to spend whatever it takes to restore the trust in Mead Johnson and our products that we fully deserve and make sure that [our consumers] understand our unwavering commitment to quality."
The broader mass-market campaign, which will only run for a few weeks and will include television advertising, will focus on Mead Johnson’s quality testing and the fact that Enfamil is the No. 1 brand recommended by pediatricians in the United States, Golsby said. "While there was no noticeable impact on our fourth-quarter sales given the late December timing, we expect to see lower market share potentially into the third quarter of this year, as those babies who switched were started on another formula age into heavier consumption period."
Other factors that will impact the infant formula market in 2012 include a trending lower birth rate, Golsby added. In addition, there are a number of WIC contracts that are open for bidding in 2012, Golsby said. WIC, the USDA’s Special Supplemental Nutrition Program for Women, Infants and Children, is one of the largest purchasers of infant formula in the United States. "The biggest contract that we currently hold is in California, which accounts for more than 14% of total WIC births," Golsby said. "California was rebid late in November, and I am pleased that we retained this contract, which will roll over effective Aug. 1. We have two other contracts that account for a total of 7% of WIC births that have yet to be bid with a rollover date of Oct. 3."
Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.
Harvard doctor calls for greater supplement regulation in NEJM
WASHINGTON — The New England Journal of Medicine on Thursday published an op-ed online that called for more rule-making to govern dietary supplements in an effort to rein in the criminal activity of illicit prescription drug manufacturers that openly disregard the laws currently in effect.
Author Pieter Cohen, author of the opinion and an assistant professor of medicine at Harvard Medical School, in his opening paragraph pointed to the recent recall of the product Zotrex. Marketed as a dietary supplement, the product reportedly contained the fictitious ingredient "Ophioglossum polyphyllous," but in actuality contained a drug analogue of the active ingredient in the erectile dysfunction pharmaceutical Viagra (sildenafil).
Following a Food and Drug Administration investigation of NovaCare, the company that distributed that product online, the U.S. Attorney’s Office in September 2011 revealed a 31-count indictment alleging NovaCare proprietor Kelly Dean Harvey purposefully thwarted FDA regulations after the agency first started warning consumers about NovaCare products in 2009 (the product at the time was called "Stiff Nights"). Charges against Harvey include one count of conspiracy, 12 counts of wire fraud, nine counts of mail fraud and nine counts of money laundering, according to reports. He pleaded not guilty to those charges in November.
"Although Zotrex represented a particularly brazen violation of the law," wrote Cohen, an assistant professor of medicine at Harvard Medical School in the opening paragraph, "surprisingly, many new supplement ingredients are introduced into the market as [those found in Zotrex were], without any regulatory oversight." Specifically, Cohen calls for clinical trials establishing safety be a pre-requisite for new dietary ingredients to reach the market.
"Unfortunately, Dr. Cohen’s article provides a bit of a bait and switch, perhaps unwittingly," claimed Duffy MacKay, VP scientific and regulatory affairs Council for Responsible Nutrition, in a statement released Thursday. "In calling for more stringent oversight of legitimate supplement products, he holds up a poster child for the problem of illegally spiked products. The product Dr. Cohen references in his commentary, by law is illegal and not a dietary supplement," he noted. "Dr. Cohen refers to the manufacturer of this product as a ‘respected company’ when in fact it is a company that broke a myriad of existing laws, including adding undeclared ingredients — specifically drugs — to the product."
In response to Cohen’s call for clinical trials vetting safety as a prerequisite, MacKay noted that, unlike pharmaceutical ingredients, supplements do not necessarily have an immediate and dramatic effect on an acute symptom or condition, "and in general, they have a wider margin of safety," he said.
Carex launches wide-grip mobile shower head
NORWELL, Mass. — Carex Health Brands recently launched its ultimate shower massager, a shower head that features a full body spray and five different massage settings.
The chrome shower head comes with an easy-to-install shower head holder, a wide showerhead handle for a secure grip and an extra-long 84-in. tangle-free hose.
The Carex ultimate shower massager will be available January 2012 online and at select retailers, independent pharmacies and drug stores at a suggested retail price of $34.99.